Drug Profile
Sildenafil oral spray - Arovella Therapeutics
Alternative Names: Duromist; NVD-401; SUD-003; SUD-004; SUDA-004; SudamistLatest Information Update: 02 Jan 2023
Price :
$50
*
At a glance
- Originator NovaDel Pharma
- Developer Arovella Therapeutics
- Class Antihypertensives; Erectile dysfunction therapies; Phenyl ethers; Piperazines; Purines; Pyrazoles; Pyrimidinones; Small molecules; Sulfonamides
- Mechanism of Action Type 5 cyclic nucleotide phosphodiesterase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Erectile dysfunction; Pulmonary arterial hypertension
Most Recent Events
- 28 Jul 2018 No recent reports of development identified for clinical-Phase-Unknown development in Erectile-dysfunction in USA (Transmucosal, Spray)
- 28 Jul 2018 No recent reports of development identified for clinical-Phase-Unknown development in Pulmonary-arterial-hypertension in USA (Transmucosal, Spray)
- 13 Aug 2013 SUDA Ltd acquires NovaDel Pharma's assets